MedTrace Logo

Photodynamic Therapy With LUZ11 in Advanced Head and Neck Cancer

NCT02070432 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-03-03

No results posted yet for this study

Summary

This study will investigate the tolerability, recommended dose and pharmacokinetics of LUZ11 following photodynamic therapy (PDT) of patients with advanced head and neck cancer.

Conditions

Interventions

DRUG

LUZ11

LUZ11 i.v. administration followed by laser light irradiation

Sponsors & Collaborators

  • Luzitin SA

    lead INDUSTRY

Principal Investigators

  • Luis Almeida, MD, PhD · Luzitin SA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070432 on ClinicalTrials.gov